The U.S. Food and Drug Administration on December 17 approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody.

Click HERE to access the press release for more information.

Please ask your doctor is this therapy is right for you.